Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6883472 | 1.00 | TYMS (0.46) | TYMSHDAC1HDAC8HDAC6DHFR | |
| SCHEMBL6886329 | 0.80 | HDAC1 (0.44) | HDAC1HDAC6KDRLNPEP | |
| SCHEMBL6886320 | 0.80 | HDAC1 (0.44) | HDAC1HDAC6KDRLNPEP | |
| SCHEMBL9088141 | 0.77 | HDAC1 (0.49) | HDAC1MAPTMEN1KMT2ANPSR1 | |
| SCHEMBL6887180 | 0.77 | CLPP (0.43) | KDRMAPTNPSR1 | |
| SCHEMBL6887186 | 0.77 | CLPP (0.43) | KDRMAPTNPSR1 | |
| SCHEMBL8725881 | 0.76 | TYMS (0.45) | TYMSKDR | |
| SCHEMBL27728858 | 0.75 | PTPRC (0.62) | ROCK2MAPTMEN1KMT2A | |
| SCHEMBL6885646 | 0.75 | POLB (0.41) | TYMSDHFRMAPTMEN1KMT2A | |
| SCHEMBL6885650 | 0.75 | POLB (0.41) | TYMSDHFRMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259878-A1 | Fluoromethotrexates and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259878-A1 | Fluoromethotrexates and uses therefor | MTX1, DHFR, SLC46A1 | TYMS 22/4885HDAC1 2847/4885HDAC8 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.